In our study, IGH-CRLF2 fusions were identified in 3/101 (2.9%) B-ALL cases without canonical B-ALL alterations or in 3/160 (1.9%) BCR-ABL1-negative B-ALL cases. The gene discussed is ABL1; the disease is precursor B-cell acute lymphoblastic leukemia.